Resumen

Objectives: Objectives: To understand the real-world patient experience and patient perceptions of prabotulinumtoxinA performance for treatment of the glabellar region. Introduction: Background- Botulinum Toxin Type A [BoNT-A] injection is the most widely performed nonsurgical cosmetic procedure in the United Kingdom [UK].PrabotulinumtoxinA is the new BoNT-A, recently licensed in the UK for treating moderate to severe glabellar lines in adults under 65. Though clinical trials have established safety and efficacy, real-world data can help clinicians translate study findings into practice and support PrabotulinumtoxinA use in a more diverse patient population. Materials / method: Methods - In this real-world, single-centre survey study, a single injector administered PrabotulinumtoxinA for treatment of glabellar lines. Two weeks after treatment, patients received surveys asking about their experience by email. There were no incentives for participation. Responses returned within five weeks of treatment were included. Results: Results - From February 2023 to June 2023, 457 patients received PrabotulinumtoxinA injections for glabellar line treatment. Survey response rate was 56% [254/457 patients]. For most patients, treatment onset was 2 to 3 days following injection, and peak response occurred after 7 to 10 days. Adverse effects were minimal, with 67% of patients experiencing none. Among survey respondents, 83% rated their treatment positively on a 5-point satisfaction scale, and 72% would choose PrabotulinumtoxinA again. Conclusion: Conclusions: These real-world data validate the safety and effectiveness of prabotulinumtoxinA in a diverse, real-world population, confirm a high level of patient satisfaction among more experienced BoNT-A patients, and suggest a rapid time to onset and peak effect.